Opus Genetics Surges 47% to 52-Week High on Positive Gene Therapy Data
IRD has more than doubled off its 52-week low of $1.32 on elevated volume (22× avg).
Summary
Opus Genetics reported positive low-dose Cohort 1 data from its Phase 1/2 BIRD-1 trial of OPGx-BEST1, with all five participants showing clinically meaningful visual improvements and four showing structural retinal recovery. The stock surged 46.66% to $6.36, a new 52-week high, reflecting strong investor enthusiasm. The company met with the FDA in August 2026 and aligned on a Phase 3 primary endpoint combining microperimetry and patient-reported outcomes, with manufacturing completion expected early 2027 and dosing later that year. A higher-dose second cohort has over-enrolled eight participants, with topline data expected in Q2 2027. New survey data suggests a global target population of 45,400 symptomatic BEST1 patients, larger than prior estimates. This follows the company's Q2 2026 report of $88.8M cash runway into 2029 and a $300M shelf registration filed in August.
At the time of this announcement, IRD was trading at $5.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $459.2M. The 52-week trading range was $1.32 to $7.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.